These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 19897063

  • 1. The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women.
    Naylor KE, Clowes JA, Finigan J, Paggiosi MA, Peel NF, Eastell R.
    Bone; 2010 Mar; 46(3):592-7. PubMed ID: 19897063
    [Abstract] [Full Text] [Related]

  • 2. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL, He JW, Qin YJ, Huang QR, Liu YJ, Hu YQ, Li M.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [Abstract] [Full Text] [Related]

  • 3. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A, Glover SJ, Eastell R.
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [Abstract] [Full Text] [Related]

  • 4. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE, Bjarnason NH, Neven P, Plouffe L, Johnston CC, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.
    Menopause; 2003 Dec; 10(4):337-44. PubMed ID: 12851517
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 9. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

  • 10. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.
    Menopause; 2006 Nov; 13(3):377-86. PubMed ID: 16735934
    [Abstract] [Full Text] [Related]

  • 16. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
    Zheng S, Wu Y, Zhang Z, Yang X, Hui Y, Zhang Y, Chen S, Deng W, Liu H, Ekangaki A, Stocks J, Harper K, Liu J.
    Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.
    Zhonghua Yi Xue Za Zhi; 2004 Feb 17; 84(4):269-73. PubMed ID: 15059505
    [Abstract] [Full Text] [Related]

  • 20. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.
    Rejnmark L, Buus NH, Vestergaard P, Heickendorff L, Andreasen F, Larsen ML, Mosekilde L.
    J Bone Miner Res; 2004 May 17; 19(5):737-44. PubMed ID: 15068496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.